A carregar...
Diffuse large B-cell lymphoma: new targets and novel therapies
Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus lenalidomide. Three CAR-T cell prod...
Na minha lista:
| Publicado no: | Blood Cancer J |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8021545/ https://ncbi.nlm.nih.gov/pubmed/33820908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00456-w |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|